Japan Medical & Health Tourism Center (JMHC) is a medical coordinator founded by the JTB group, the greatest travel company in Japan, to be a bridge between foreign patients who had been prevented from visiting Japan by the barrier of language, visas, etc., and excellent medical treatment in Japan.
Foreign patients had been worried about the types of medical checkups or treatment available in Japan or what medical care they could receive during a visit to Japan because of lack of information abroad. Since its inception in April 2010, we have provided such people with various services from inquiries and hospitalization to discharge, such as multilingual support and the travel service through the foreign network of JTB, by fully utilizing JTB group resources in cooperation with Japanese medical institutions in order to realize secure and smooth medical trips to Japan .
To accomplish this purpose, we acquired the Japan Tourism Agency's first license as registered guarantors (JTA Registration No. A-001) for the Visa for Medical Stay, which foreign patients are required to obtain to receive medical treatment in Japan. Moreover we joined the Medical Excellence JAPAN (MEJ), a government-affiliated organization, and concerning the Japanese certification system of Accredited Medical Travel Assistance Company, we also acquired the first license (authentication number MEJ-AMTAC-001).
We aim to be a medical coordinator reliably chosen by foreign patients providing secure, safe, and valuable services to people who visit Japan for medical care or health promotion in alliance with medical institutions, medical/health organizations and government offices and companies inside and outside Japan.
Director of Japan Medial & Health Tourism Center (JMHC)
Business Development Division, JTB Corporation
As noted in a report by Kumarasamy et al. (2010), however, there are some who may associate medical treatment performed overseas with the problems of infectious diseases. In fact, there certainly was an example of an infectious disease contagion that was reported, namely, NDM-1：New Delhi metallo-beta-lactamase-1.* We intend to respond very carefully to the existence of this type of risk, and together with Japanese medical institutions that promote accepting foreign patients, to continue providing services going forward as well.
By providing added value service to foreign patients who come to Japan for the purpose of medical treatment, we aim to address medical care issues and enhanced health for foreign patients and further develop medical care in Japan.
※Kumarasamy, KK. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular biological, and epidemiological study.Lancet Infect Dis. 10, 2010, 597-602.